Global Virus Network Expands Global Capacity with New Centers of Excellence in Brazil and Florida
Brazil's Universidade Federal de Minas Gerais and the University of Florida College of Medicine Named Newest Centers of Excellence
TAMPA, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- The Global Virus Network (GVN), an international coalition of eminent human and animal virologists from 80+ Centers of Excellence and Affiliates in 40+ countries, announced today the addition of two distinguished organizations to its global consortium. The Center for Advanced and Innovative Therapies at the Universidade Federal de Minas Gerais (UFMG) in Brazil and the University of Florida (UF) College of Medicine's Department of Pathology, Immunology, and Laboratory Medicine have been named GVN Centers of Excellence.
'This expansion marks another step forward in GVN's mission to unite the world's foremost virologists in the pursuit of solutions to global viral threats,' said Dr. Robert C. Gallo, chairman of the Scientific Leadership Board and co-founder of the GVN. 'Both institutions bring deep regional expertise, scientific excellence, and a strong commitment to collaboration. Their inclusion strengthens our collective scientific capacity and enhances the global infrastructure needed to detect, respond to, and ultimately prevent future viral outbreaks.' Dr. Gallo, who is most widely known for his co-discovery of HIV as the cause of AIDS, is also the James P. Cullison Professor of Medicine, director of the USF Health Virology Institute at the University of South Florida, and director of the Microbial Oncology Program at Tampa General Hospital (TGH) Cancer Institute.
The Universidade Federal de Minas Gerais (UFMG), one of Brazil's oldest and most respected academic institutions, has a long-standing legacy in education, research, and public service. Its Center for Advanced and Innovative Therapies focuses on viruses of regional and global importance, including arboviruses, poxviruses, influenza, and hantaviruses. UFMG houses two National Institutes of Science and Technology (INCT), INCT Dengue and INCT Pox, and operates BSL-2 and BSL-3 labs for in vitro and animal model studies. The Center has extensive expertise in viral genomics, vaccine development, and clinical testing, and plays a critical role in Brazil's infectious disease research network.
'Joining the Global Virus Network is a milestone for our center and a recognition of Brazil's critical role in the global fight against infectious diseases,' said Dr. Mauro Martins Teixeira, director of the new Center of Excellence at the GVN and professor of immunology at UFMG. 'Our team at UFMG is dedicated to developing innovative therapies and vaccines targeting neglected and emerging viruses. We are eager to expand our international collaborations and accelerate impactful research that benefits both regional and global communities.'
The University of Florida (UF) College of Medicine's Department of Pathology, Immunology, and Laboratory Medicine is a leader in clinical diagnostics, pathology education, and experimental virology research. Closely affiliated with the UF Emerging Pathogens Institute (EPI), the department conducts extensive research on pathogens of public health importance, including HIV, SARS-CoV-2, and vector-borne viruses. EPI houses twelve BSL-3/BSL-3+ laboratories, a BSL-3 greenhouse, and a satellite BSL-3 site in Haiti. Their next-generation sequencing and high-performance data infrastructure support global collaborations on virus evolution, transmission, and control.
'Becoming a GVN Center of Excellence underscores the University of Florida's long-standing commitment to global virology and public health,' said Dr. Marco Salemi, director of the new Center of Excellence at the GVN and professor of Experimental Pathology at UF College of Medicine. 'Through our integrated approach combining clinical diagnostics, high-containment research, and advanced genomic technologies, we aim to contribute meaningful solutions to global viral threats. We are excited to collaborate across the GVN network to foster scientific exchange and innovation.'
Media Contact:Nora Samaranayakensamaranayake@gvn.org
About the Global Virus Network The Global Virus Network (GVN) is a worldwide coalition comprising 80+ Virology Centers of Excellence and Affiliates across 40+ countries, whose mission is to facilitate pandemic preparedness against viral pathogens and diseases that threaten public health globally. GVN advances knowledge of viruses through (i) data-driven research and solutions, (ii) fostering the next generation of virology leaders, and (iii) enhancing global resources for readiness and response to emerging viral threats. GVN provides the essential expertise required to discover and diagnose viruses that threaten public health, understand how such viruses spread illnesses, and facilitate the development of diagnostics, therapies, and treatments to combat them. GVN coordinates and collaborates with local, national, and international scientific institutions and government agencies to provide real-time virus informatics, surveillance, and response resources and strategies. GVN's pandemic preparedness mission is achieved by focusing on Education & Training, Qualitative & Quantitative Research, and Global Health Strategies & Solutions. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
13 hours ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


The Hill
a day ago
- The Hill
Obamacare preventive care mandate wins in Supreme Court ruling
The Big Story The Supreme Court on Friday upheld a key Affordable Care Act requirement that insurance companies cover certain preventative measures recommended by an expert panel. © AP Justices upheld the constitutionality of the provision in a 6-3 decision and protected access to preventative care for about 150 million Americans. The justices found that the secretary of the Department of Health and Human Services has the power to appoint and fire members of the U.S. Preventative Services Task Force (USPSTF). The cases started when a small business in Texas and some individuals filed a lawsuit against the panel's recommendation that pre-exposure prophylaxis (PreP) for HIV be included as a preventative care service. They argued that covering PreP went against their religious beliefs and would 'encourage homosexual behavior, intravenous drug use, and sexual activity outside of marriage between one man and one woman.' The plaintiffs further argued that the USPSTF mandates are unconstitutional because panel members are 'inferior officers' who are not appointed by the president or confirmed by the Senate. While the panel is independent, they said that since their decisions impact millions of people members should be confirmed. A U.S. district judge in 2023 ruled that all preventative-care coverage imposed since the ACA was signed into law are invalid and a federal appeals court judge ruled in agreement last year. The Biden administration appealed the rulings to the Supreme Court, and the Trump administration chose to defend the law despite its long history of disparaging Obamacare. Though public health groups celebrated the ruling Friday, some noted another potential outcome. 'While this is a foundational victory for patients, patients have reason to be concerned that the decision reaffirms the ability of the HHS secretary, including our current one, to control the membership and recommendations of the US Preventive Services Task Force that determines which preventive services are covered,' Anthony Wright, executive director of Families USA, said in a statement. 'We must be vigilant to ensure Secretary Kennedy does not undo coverage of preventive services by taking actions such as his recent firing of qualified health experts from the CDC's independent vaccine advisory committee and replacing them with his personal allies.' Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Joseph Choi and Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: New Hampshire lawmakers give final approval to gender-affirming care ban New Hampshire lawmakers on Thursday gave final approval to bills that would ban gender-affirming care for transgender minors in the state, sending the measures to Republican Gov. Kelly Ayotte, who has not yet said whether she will sign them. State lawmakers voted to pass House Bill 377, which would prohibit doctors from administering puberty blockers and hormones to transgender youth beginning next year. The measure includes … FDA expanding COVID vaccine warnings over rare heart side effect The U.S. Food and Drug Administration is now requiring two common COVID-19 vaccines to update their warning labels to include information on two rare heart side effects. Myocarditis, or inflammation of the heart muscle, and pericarditis, or inflammation of the thin sac surrounding the heart — are two conditions that a small number of people have experienced after receiving the mRNA COVID-19 shot. The rare cases of myocarditis … What causes a stroke? Learn the triggers and risk factors Most Americans likely know at least a little about the signs of a stroke. While early intervention is vital for a positive outcome, medical experts also stress the need to prevent strokes, which the Stroke Foundation reports are the fifth leading cause of death in the U.S. The key to prevention is knowing what causes these brain attacks. According to the American Heart Association, a stroke occurs when a blood vessel to the … In Other News Branch out with a different read from The Hill: GOP leader sets Saturday vote on Trump 'big, beautiful bill' despite Republican pushback Senate Majority Leader John Thune (R-S.D.) told Senate Republicans to expect to see the legislative text of the budget reconciliation package on Friday evening and then to vote at noon Saturday to begin debate on President Trump's tax and spending bill. Around the Nation Local and state headlines on health care: What We're Reading Health news we've flagged from other outlets: What Others are Reading Most read stories on The Hill right now: GOP leader sets Saturday vote on Trump 'big, beautiful bill' despite Republican pushback Senate Majority Leader John Thune (R-S.D.) told Senate Republicans to expect to see the legislative text of the budget reconciliation package on Friday … Read more 5 takeaways from the Supreme Court's birthright citizenship ruling The Supreme Court handed President Trump a clear victory Friday, stopping judges from issuing nationwide injunctions that block his executive order … Read more What People Think Opinions related to health submitted to The Hill: Thank you for signing up! Subscribe to more newsletters here